A MARK OF EXCELLENCE!HANSOHPHARMACEUTICAL SECURES A TOP THREE SPOT AMONG "MODEL INDUSTRIAL ENTERPRISES FOR CHINA’S PHARMACEUTICAL R&D PIPELINES" FOR THE TENTH CONSECUTIVE YEAR.
From July 11 to 12, the China Pharmaceutical Industry Information Annual Conference, widely regarded as a key benchmark event for China's pharmaceutical industry, was held in Beijing. During the conference, a number of authoritative industry rankings and benchmark case studies were released. Thanks to its substantial investment in R&D and solid business performance,HansohPharmaceutical climbed to 25th place in the “2025 Top 100 Chinese Pharmaceutical Industrial Enterprises by Main Business Revenue” ranking. In addition, the company once again ranked among the Top Three of “Model Industrial Enterprises forChina'sPharmaceutical R&D Pipelines”, marking its tenth consecutive year in the top three.
Based on data from the Ministry of Industry and Information Technology (MIIT)’s2025 Statistical Yearbook of China's Pharmaceutical Industry, the conference also released the "2025 Top 100 Chinese Pharmaceutical Industrial Enterprises by Main Business Revenue " ranking. As a leading innovation-driven pharmaceutical company in China,HansohPharmaceutical is dedicated to addressing major disease areas, including oncology, anti-infectives, central nervous system disorders, metabolic diseases, and autoimmune diseases. Driven by its solid business performance, the firm advanced from 30th to 25th place in the industry's Top 100 ranking.
HansohPharma continues to scale up its investment in research and development. In 2025, R&D expenditure accounted for 22.3% of its operating revenue. The Company is simultaneously conducting more than 70 clinical trials for innovative medicines covering over 40 innovative drug candidates currently under development.HansohPharma has remained among the Top Three of "Model Industrial Enterprises for China’s Pharmaceutical R&D Pipelines " for ten consecutive years, demonstrating its continued leadership in driving innovation and the advancing pharmaceutical R&D throughout the Chinese pharmaceutical sector.
In terms of sustainability,HansohPharma's “Lean Manufacturing as the Foundation of Corporate Social Responsibility” program, built on its integrated end-to-end operating model, was recognized as one of the “Outstanding Corporate Social Responsibility Cases in China's Pharmaceutical Industry” at this year's conference. The firm continues to refine its corporate governance framework and has been awarded honors including National Green Factory and a National Green Supply Chain Management Enterprise, among other honors. It also secured the top AAA rating in the MSCI ESG assessment, reflecting the successful integration of green intelligent manufacturing and responsible business practices.
To further advance global pharmaceutical innovation and improve equitable access to medicines, the opening ceremony of this year's conference witnessed the launch of the 2026 Key Actions of the Initiative for Global Collaboration in the Pharmaceutical Industry. The initiative was jointly inaugurated by cross-sector representatives from government, industry, academia, and research institutions, including Academicians RaoZihe, CaoXuetao, and DongJiahong, as well as Dr.LyuAifeng, Executive Director ofHansohPharmaceutical Group. At the conference's main forum, Dr.LyuAifengdelivered a keynote address, sharing the firm’s strategies for innovation-driven R&D and global layout.
From R&D leadership and green intelligent manufacturing to global collaboration,HansohPharma's multifaceted presence at this year's conference underscored not only its comprehensive strengths as a leading innovative pharmaceutical company, but also reflected the accelerating transformation of China's pharmaceutical industry from imitative innovation to original innovation. Looking ahead,HansohPharma will remain committed to high-quality development and continue to contribute Chinese strengths to global healthcare advancement.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
